mRNA |
alisertib:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.061 |
0.08 |
mRNA |
GDC-0449 |
GDSC1000 |
pan-cancer |
AAC |
-0.061 |
0.08 |
mRNA |
erastin |
CTRPv2 |
pan-cancer |
AAC |
-0.06 |
0.08 |
mRNA |
KIN001-270 |
GDSC1000 |
pan-cancer |
AAC |
0.058 |
0.08 |
mRNA |
carboplatin:etoposide (40:17 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.051 |
0.08 |
mRNA |
Bax channel blocker |
CTRPv2 |
pan-cancer |
AAC |
-0.066 |
0.08 |
mRNA |
navitoclax:MST-312 (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.062 |
0.08 |
mRNA |
BRD-A02303741:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.061 |
0.08 |
mRNA |
PRIMA-1-Met |
CTRPv2 |
pan-cancer |
AAC |
-0.09 |
0.08 |
mRNA |
Compound 23 citrate |
CTRPv2 |
pan-cancer |
AAC |
-0.058 |
0.08 |